Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems

XPO1 has recently emerged as a viable treatment target for solid malignancies, including glioblastoma (GBM), the most common primary malignant brain tumor in adults. However, given that tumors become commonly resistant to single treatments, the identification of combination therapies is critical. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Enyuan, Zhang, Yiru, Shu, Chang, Ishida, Chiaki Tsuge, Bianchetti, Elena, Westhoff, Mike-Andrew, Karpel-Massler, Georg, Siegelin, Markus D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194027/
https://www.ncbi.nlm.nih.gov/pubmed/30337641
http://dx.doi.org/10.1038/s41598-018-33784-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194027/
https://www.ncbi.nlm.nih.gov/pubmed/30337641
http://dx.doi.org/10.1038/s41598-018-33784-2

Ejemplares similares